PTCD1

Across TCGA pan-cancer cohorts, PTCD1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PTCD1 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PTCD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTCD1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

CESC, LIHC, and ACC are the cancer types where PTCD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.151	0.801	<.001	36	view →
LIHC	DFS	Median	All	0.081	0.527	.012	18	view →
ACC	OS	Median	All	0.135	0.632	.001	12	view →
UCEC	DFS	Median	All	0.929	0.630	.019	10	view →
BLCA	OS	Median	III,IV	0.861	0.339	.019	5	view →
STAD	DFS	Median	II,III,IV	1.000	0.371	.040	4	view →
COAD	DFS	Median	All	0.212	0.696	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PTCD1–CESC (OS)

Open the CESC breakdown →